Ionis Pharmaceuticals: The Heartbreak Is Priced In (NASDAQ:IONS)
· seekingalpha.com
Ionis is rated a Buy with a valuation offering attractive upside despite reimbursement, competition, and execution risks. Read more on IONS stock here.
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...